Previous Close | 20.00 |
Open | 20.21 |
Bid | 19.58 x 100 |
Ask | 20.52 x 100 |
Day's Range | 19.71 - 20.55 |
52 Week Range | 7.58 - 21.44 |
Volume | |
Avg. Volume | 47,904 |
Market Cap | 253.238M |
Beta (5Y Monthly) | 3.11 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.70 |
Earnings Date | Mar 31, 2024 - Apr 04, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 36.00 |
STAFFORD, Texas, March 13, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that its Board of Directors has extended the lock-up of the shares owned by the Company's directors, officers, and existing pre-IPO investors to June 30, 2025 which is approximately 57 mont
STAFFORD, Texas, March 12, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the initiation of the first clinical sites in Europe in collaboration with GEICAM in Spain. The Company has partnered with GEICAM, the largest academic breast cancer research network in Spa
Greenwich LifeSciences Inc (NASDAQ:GLSI) has reported an insider purchase by CEO and CFO, 10% Owner Snehal Patel, according to a recent SEC filing.